Bevacizumab extends progression-free survival in women with advanced ovarian cancer
Links shared publicly online about this topic.
- 1,112total visits
Bevacizumab extends progression-free survival in women with advanced ovarian cancer
View full resource at news-medical.net
Tags: Cancer, Chemotherapy, Colorectal Cancer Medication, Ovarian Cancer, Drug, Clinical Trial, Women's Health, Avastin
Most Recently Shared on June 7, 2010 at 12:55 pm By:
Ovarian Cancer News: Bevacizumab extends progression-free survival in women with advanced ovarian cancer: Newly ... http://buzzup.com/zltp
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - MPR
empr.com — “Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.” View full resource at empr.com
Most Recently Shared on June 5, 2011 at 6:53 pm By:
#asco2011 Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in… http://goo.gl/fb/MUWQq
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - ONA
oncologynurseadvisor.com — “Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 5, 2011 at 6:30 pm By:
OncologyNurseAdvisor Medical Education, Medical Publisher, Oncology, and Nursing
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent… http://goo.gl/fb/oUkM7
Medical News: ESMO: Ovarian CA Responds to Bevacizumab - in Meeting Coverage, ESMO from MedPage Today
medpagetoday.com — “MILAN -- Women with high-risk early or advanced ovarian cancer gained almost two months in progression-free survival (PFS) when the angiogenesis inhibitor bevacizumab (Avastin) was added to chemothera” View full resource at medpagetoday.com
Most Recently Shared on October 13, 2010 at 11:09 pm By:
ESMO: Ovarian CA Responds to Bevacizumab (CME/CE) http://bit.ly/cCiyBY
Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer
news-medical.net — “Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.” View full resource at news-medical.net
Most Recently Shared on June 7, 2010 at 12:55 pm By:
Ovarian Cancer News: Genentech reports results from Phase III study of Avastin in women with advanced ovarian ca... http://buzzup.com/zltn
New treatment regimen shown effective against advanced ovarian cancer
eurekalert.org — “Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.” View full resource at eurekalert.org
Most Recently Shared on June 6, 2010 at 6:53 pm By:
New treatment regimen shown effective against advanced ovarian cancer: (Fox Chase Cancer Center) Newly reported re... http://bit.ly/a8Fohc
New treatment regimen shown effective against advanced ovarian cancer
physorg.com — “Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment ...” View full resource at physorg.com
Most Recently Shared on June 6, 2010 at 4:50 pm By:
PhysOrg Health News Health News
New treatment regimen shown effective against advanced ovarian cancer http://tw.physorg.com/195047400
Medical News: Bevacizumab Slows Ovarian Cancer Progression - in Hematology/Oncology, Other Cancers from MedPage Today
medpagetoday.com — “Maintenance therapy with bevacizumab (Avastin) following combination therapy with the drug and chemotherapy improved progression-free survival in women with previously untreated advanced ovarian cance” View full resource at medpagetoday.com
Most Recently Shared on February 26, 2010 at 1:12 am By:
Bevacizumab Slows Ovarian Cancer Progression Maintenance therapy with bevacizumab (Avastin) following combination the.. http://bit.ly/andCCr
Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS
buzzup.com — “Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avasti” View full resource at buzzup.com
Most Recently Shared on February 25, 2010 at 6:28 pm By:
Ovarian Cancer News: Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improv... http://buzzup.com/oyli_
Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS
news-medical.net — “Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.” View full resource at news-medical.net
Most Recently Shared on February 25, 2010 at 10:40 am By:
Pregnancy News: Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS: ... http://bit.ly/aOjZqK
Advertisement
